Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $255.0 million
Deal Type : Licensing Agreement
EraCal Therapeutics Enters into a Collaboration and License Agreement with Novo Nordisk
Details : Under the agreement, Novo Nordisk has obtained all exclusive rights to develop and commercialize EraCal’s oral small molecule asset to control appetite and body weight.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 23, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $255.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Collaboration
EraCal Therapeutics Enters into Research Collaboration with Novo Nordisk
Details : Under the joint research plan, EraCal and Novo Nordisk will investigate novel molecules for their potential as anti-obesity pharmacotherapy. This will be done in zebrafish larvae, an emerging vertebrate drug discovery platform.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
January 17, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
